» Articles » PMID: 29455075

Prevalence of Multiple Sclerosis in Poland

Overview
Specialty Neurology
Date 2018 Feb 19
PMID 29455075
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The prevalence of multiple sclerosis (MS)was previously unknown in Poland. The aim of this study was to determine the prevalence of MS in Poland.

Methods: MS prevalence was determined on the basis of data from the Swietokrzyskie (central Poland) and Podlaskie (northeastern Poland) Voivodeships. The area population on the prevalence study day (December 31, 2013) was 1,268,239 (649,007 women; 619,232 men) in central and 1,195,625 (612,979 women; 582,646 men) in northeastern Poland.

Results: The overall crude prevalence rate of confirmed MS patients was 109.1/100,000 (95% confidence interval[CI]103.5-115.0) in the Swietokrzyskie and 108.7/100,000 (95% CI 103.0-114.7) in the Podlaskie Voivodeships. A significantly higher prevalence was recorded in females (149.8/100,000, 95% CI 140.6-159.3 vs. 142.4/100,000, 95% CI 133.3-152.0) than in males (66.5/100,000, 95% CI 60.4-73.1 vs.57.8/100,000, 95% CI 52.0-64.2)(p < 0.001). Age-adjusted rates for the Polish Standard Population were the same in both regions (110.3/100,000 (95% CI 104.6-116.1) vs.110.9/100,000 (95% CI 105.1-117.1)) and for the European Standard Population did not different statistically between both voivodeships (103.9/100,000 (95% CI 98.6-109.5) vs.108.5/100,000 (95% CI 102.7-114.5)).

Conclusion: This is the first data that obtained the level of MS prevalence in Poland and confirmed that Poland is a high-risk area for multiple sclerosis.

Citing Articles

Monitoring of the pharmacological treatment availability in patients with multiple sclerosis in the Greater Poland population.

Daroszewski P, Kaczmarek K, Huber J Reumatologia. 2024; 61(6):473-480.

PMID: 38322107 PMC: 10839914. DOI: 10.5114/reum/177143.


Epidemiological parameters of multiple sclerosis in Chaharmahal and Bakhtiari Province, Iran.

Omrani M, Bayati A, Sahraian M, Eskandarieh S Curr J Neurol. 2023; 22(2):103-109.

PMID: 38011364 PMC: 10460920. DOI: 10.18502/cjn.v22i2.13337.


Clinical Characteristics of Headache in Multiple Sclerosis Patients: A Cross-Sectional Study.

Rosciszewska-Zukowska I, Galiniak S, Bartosik-Psujek H J Clin Med. 2023; 12(10).

PMID: 37240624 PMC: 10219221. DOI: 10.3390/jcm12103518.


The Clinical and Epidemiological Profile of Paediatric-Onset Multiple Sclerosis in Poland.

Brola W, Steinborn B, Zak M, Mazurkiewicz-Beldzinska M, Jozwiak S, Sobolewski P J Clin Med. 2022; 11(24).

PMID: 36556109 PMC: 9785459. DOI: 10.3390/jcm11247494.


Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies.

Bizon A, Chojdak-Lukasiewicz J, Koltuniuk A, Budrewicz S, Pokryszko-Dragan A, Piwowar A Antioxidants (Basel). 2022; 11(12).

PMID: 36552624 PMC: 9774652. DOI: 10.3390/antiox11122416.